Precision StemCell has partnered with Neuralgene to evaluate the effectiveness of PRCN-829 gene therapy for the treatment of ALS. This gene therapy can be combined with stem cell therapy. PRCN-829 is a neurotrophic AAV gene therapy that inhibits Complement and helps eliminate toxic protein build up from TDP-43.

In addition, Precision StemCell is performing research in the specific underlying genetic abnormalities of ALS. It is hoped that this work will lead to individual genetic testing, which can result in gene therapy that is directed for each particular underlying cause of that patient’s ALS. ALS is a complex disease, which is associated with multiple abnormal genes and proteins. These can be highly variable from patient to patient. It is likely that the most effective therapy will have to be individually made for each patient to treat his or her specific abnormalities.

Precision StemCell is involved in culturing with reprogramming of stem cells. The stem cells can be exposed to certainly growth factors which improve their effectiveness for the specific disease to be treated.